What Happens If Your GLP-1 Telehealth Platform Shuts Down Tomorrow

This isn't hypothetical. In 2026, the FDA has issued 30+ warning letters to telehealth companies, referred the industry's largest player to the DOJ, and proposed closing the last legal pathway for large-scale GLP-1 compounding. Hims pulled a product within days of launch. Multiple smaller platforms have quietly paused operations.

If your telehealth provider goes dark — whether from an FDA enforcement action, a business closure, or a strategic pivot away from GLP-1 — you need to keep your treatment going. Here's how.

What You Should Do Right Now (Before Anything Happens)

1. Get Your Medical Records

Under HIPAA, you have the legal right to your medical records. Request your complete file from your current provider — consultation notes, prescription history, dose titration records, and any lab results. Store these locally (email a copy to yourself, save as PDF). If the platform shuts down, their patient portal may become inaccessible.

2. Document Your Current Prescription

Know your exact medication (compounded semaglutide vs. tirzepatide), current dose, injection frequency, and how long you've been at this level. Write it down. Your new provider needs this information to maintain dose continuity.

3. Identify a Backup Provider Now

Don't wait for a crisis to start shopping. Research one or two alternative platforms, complete their intake assessments if possible, and have them ready to activate. The transfer is much smoother when you're not scrambling.

4. Understand What You Own

Your prescription belongs to you, not the platform. Your medical records belong to you. Your remaining medication supply is yours. A platform closing doesn't invalidate your existing prescription — though a new provider may need to write a new one based on their own evaluation.

What Happens to Your Medication Supply

Medication you've already received is yours. It doesn't expire or become illegal because the platform that facilitated the prescription changes status. Continue your current supply as directed while you establish care with a new provider.

However, you won't be able to get refills through a closed platform. This is why having a backup provider matters — the goal is zero gap between your last refill from the old platform and your first shipment from the new one.

The Foundayo Fallback

One significant development that changes the calculus: Foundayo (orforglipron) was FDA-approved on April 1, 2026. It's an oral GLP-1 pill at $149/month self-pay, or as low as $25/month with a savings card. It can be prescribed by any licensed provider and filled at any pharmacy. If the compounded market contracts significantly, Foundayo represents a legitimate FDA-approved alternative at a price point comparable to many compounded options.

Build Your Safety Net